Clinical supply data reveals where protocol assumptions break down. Could those lessons help improve protocol design and reduce avoidable amendments?
- AI Is Only As Good As The Data Behind Your Clinical Trial Supply Chain
- Five Places Where AI Stalls In Clinical Supply
- ADC CDMO Selection For Small Biotech
- More Than Half The Drug We Make Never Reaches A Patient
- Lessons In Forecasting Discipline From A $40B Supply Chain
- Clinical Supply When There's No Drug To Ship
- Why Clinical Supply Problems Rarely Start In Clinical Supply
- The Last Mile Nobody Talks About: What Really Happens To Unused Clinical Trial Supplies
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Overcoming Cell Therapy Supply Chain Challenges
For the industry to realize the potential of cell and gene therapies (CGTs), we must develop improved solutions that reliably support the control and transport of critical CGT raw materials and products.
-
Leveraging A Demand-Led Clinical Supply Model For Program-Level Product Pooling
See how a global biopharmaceutical company was able to address inefficiencies and reduce waste within the clinical supply chain for a high-value therapy that faced strong demand but limited supply.
-
RTSM Reusability: What It Is, Why Most Systems Lack It, And Why It Matters
Explore why RTSM should be viewed as a system for managing change. Learn how platform-based reusability reduces UAT churn, preserves institutional memory, and stabilizes mid-study amendments.
-
How Clinical Trial Complexity Impacts End Users
This article examines clinical trial complexity through the lens of study investigators, site staff, CRAs, sponsor study and supply managers, and how the RTSM/ IRT provides the ability to be as creative as needed.
-
24/7 Cell & Gene Control Tower Provides Agile Solution For Critical Shipments
Get an overview of a successful re-route of six critical shipments to the UK and Spain from Amsterdam used to deliver CAR-T drug products to treat non-Hodgkin’s lymphoma cancer patients.
-
Key Considerations For Labeling Your Cell Or Gene Therapy
As sponsors focus on maintaining the temperature range required for cell and gene therapies, they must also keep in mind the challenges this task presents when properly labeling them for clinical trial distribution.
-
Safeguarding Cell Therapy Cryopreservation: Primary Containers
Review different aspects of container selection from the perspective of cryopreservation that are may be overlooked but critical for the quality of cell therapy drug products.
-
When Every Hour Counts: Emergency Transfer Protects Critical Biomedical Materials
Rapid deployment of specialized cold chain logistics and cryogenic assets ensures strict temperature compliance, protecting critical research continuity and preventing catastrophic material loss.
-
Technology Solutions That Help Optimize Clinical Trial Distribution And Supply
Explore how interactive response technology (IRT) can solve some common challenges of manually managed clinical trials and how to find the best IRT solution that meets clinical trial requirements.
-
From Frustration To Organization: An SSO Platform For Trial Sites
To reap the benefits of tech innovation, sponsors and sites need a single sign-on (SSO) solution that enables streamlined organization across different trials and clinical systems.
- Could Smarter Use of Clinical Supply Data Help Avoid Certain Protocol Amendments?
- Can Your Operating Model Grow? Preparing Clinical Supply For What Comes Next
- The Biggest Early-Stage Clinical Supply Mistake? Building Too Much, Too Soon.
- How Clinical Supply Is Shaping The Next Generation Of Cell And Gene Therapies
CATALENT CORNER
| Insights from Catalent's Clinical Supply Experts |
SPONSORED CONTENT
Impact Of Supplier Choice On APAC Clinical Trial Execution
Learn about strategies Asia-Pacific has become an increasingly complex and congested destination for clinical trials as local and global sponsors alike flock to the region to take advantage of its many benefits, including access to large patient pools. Choosing the right clinical packaging and supply chain partner to support these studies is critical and can vary significantly based upon what countries are involved and the types of services required.